华大基因(300676) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥1,352,666,560.15, a decrease of 10.17% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2022 was ¥141,442,691.01, down 56.91% year-on-year[3]. - The basic earnings per share for Q3 2022 was ¥0.3450, reflecting a decline of 56.91% compared to the previous year[3]. - Total revenue for Q3 2022 decreased significantly, with a net cash flow from operating activities of -192,762,670.60 RMB, a decline of 110.98% compared to the previous year[6]. - The net profit for Q3 2022 was CNY 746,723,722, a decrease of 47.9% compared to CNY 1,431,148,673 in Q3 2021[25]. - The total operating profit for Q3 2022 was CNY 883,405,815.97, down 47.7% from CNY 1,688,236,458.10 in the same quarter last year[25]. - The company reported a total comprehensive income of CNY 1,099,928,135.81 for Q3 2022, compared to CNY 1,444,963,979.82 in Q3 2021, indicating a decrease of 23.9%[25]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥13,882,089,791.52, a decrease of 2.61% from the end of the previous year[3]. - Total liabilities decreased to CNY 3,798,205,505.34 from CNY 4,812,756,470.14, representing a reduction of 21.01%[23]. - The equity attributable to shareholders increased by 6.82% to ¥9,954,131,817.56 compared to the end of the previous year[3]. - The company's total current assets amounted to RMB 10.0946 billion, a decrease from RMB 11.0348 billion at the beginning of the year[21]. - The company's cash and cash equivalents were RMB 5.9561 billion, down from RMB 6.5903 billion at the beginning of the year, reflecting a decrease of approximately 9.6%[21]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥670,395,318.71, down 49.01% year-on-year[3]. - The cash flow from operating activities showed a net outflow of CNY -192,762,670.60, contrasting with a net inflow of CNY 1,755,451,570.56 in the same period last year[27]. - The net cash flow from investing activities was CNY 410,352,271.84, a significant improvement from the net outflow of CNY -1,277,916,569.02 in the previous year[28]. - The company incurred a net cash outflow from financing activities of CNY -1,106,930,002.94, compared to a net inflow of CNY 1,087,209,592.12 in Q3 2021[28]. Inventory and Receivables - Inventory increased by 41.91% to ¥1,245,605,599.42, attributed to higher stock levels of finished goods and raw materials[5]. - Accounts receivable increased to RMB 1.4433 billion from RMB 1.2149 billion, representing a growth of approximately 18.8%[21]. Investments and R&D - R&D expenses for the quarter were CNY 393,032,758.56, up from CNY 354,898,676.34, reflecting a year-over-year increase of 10.73%[24]. - The company plans to continue investing in R&D and expanding its market presence, focusing on new product development and technological advancements[24]. - The company invested RMB 60 million in Wuhan Huada Jinuo Biotechnology Co., acquiring a 5.4545% equity stake after the capital increase, which raised the registered capital to RMB 2.61392 million[16]. - The company invested RMB 30 million in Shenzhen Hemu Gene Biotechnology Co., obtaining a 13.04% equity stake after the capital increase, which raised the registered capital to RMB 4.166667 million[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 79,439, with the largest shareholder holding 35.94% of the shares[7]. - The company repurchased shares for employee stock ownership plans, leading to a significant cash outflow of -1,106,930,002.94 RMB from financing activities, a decline of 201.81%[6]. - The first phase of the employee stock ownership plan had 2,000,000 shares unlocked, accounting for 0.4832% of the total share capital[15]. Market and Product Development - The company is focusing on the development and promotion of products for the prevention of birth defects, targeting various stages of pregnancy and early childhood[12]. - New product launches, including NIFTY®全因 4.0 and low-cost non-invasive liver cancer gene detection products, contributed to revenue growth in carrier screening and newborn genetic screening[13]. - The company received CE certification for several products, including CNV-seq and PM Easy Lab, enhancing its international business expansion[13]. - The company is establishing a local joint venture in Saudi Arabia to support the development of the third-party medical testing market[13]. Financial Adjustments - The company adjusted the internal investment structure of its fundraising project for the Qingdao Huada Gene testing reagent production and gene testing service project, without changing the project implementation主体 or the use of raised funds[20]. - Deferred income decreased by 34.93% to 23,472,250.23 RMB, primarily due to the transfer of government grants[6].